Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BY-NC 4.0Dermatology and Therapy

Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials

  • Andrew E. Pink1
  • Zakiya P. Rice2
  • Melinda J. Gooderham3,4,5
  • Fang Wang6
  • Andreas Wollenberg7,8,9
  • Pinaki Biswas10
  • Gary Chan11
  • Justine Alderfer12
  • Melissa Watkins10
12 affiliations
  1. 1St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, Floor 2, Counting House, Guy’s Hospital, London, SE1 9RT UK
  2. 2Dermatology Associates of Georgia, Atlanta, GA USA
  3. 3SKiN Centre for Dermatology, Peterborough, ON Canada
  4. 4Queen’s University, Kingston, ON Canada
  5. 5Probity Medical Research, Waterloo, ON Canada
  6. 6Dermatology Hospital, Southern Medical University, Guangzhou, China
  7. 7University Hospital Augsburg, Augsburg, Germany
  8. 8Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany
  9. 9Ludwig Maximilian University, Munich, Germany
  10. 10Pfizer Inc., New York, NY USA
  11. 11Pfizer Inc., Groton, CT USA
  12. 12Pfizer Inc., Collegeville, PA USA
Read full textPDFDOICite

Abstract

Introduction: Baseline severity of atopic dermatitis (AD) may influence treatment response. The objective of this analysis was to assess short- and long-term abrocitinib efficacy and safety by baseline AD severity.

Methods: A post-hoc analysis of patients (aged ≥ 12 years) with moderate-to-severe AD receiving abrocitinib 100 mg or 200 mg or placebo in two studies—JADE COMPARE (ClinicalTrials.gov ID: NCT03720470) and JADE EXTEND (NCT03422822)—was performed. Baseline severity was assessed by several measures, including the Investigator’s Global Assessment (IGA) and the Eczema Area and Severity Index (EASI). Efficacy and safety endpoints were stratified by baseline severity.

Results: Higher proportions of patients with moderate or severe baseline AD achieved IGA score 0/1 (clear/almost clear) with abrocitinib at week 16 (moderate: 40.8% [100 mg], 50.0% [200 mg]; severe: 19.1% [100 mg], 43.2% [200 mg]) versus placebo (moderate: 18.0%; severe: 2.8%). At week 112, IGA 0/1 was achieved by high proportions of patients receiving abrocitinib with moderate (60.2% [100 mg], 64.3% [200 mg]) or severe (38.6% [100 mg], 54.5% [200 mg]) disease. Response rates were similar with other measures, including co-achievement of EASI-90 (90% improvement from baseline score) and Peak Pruritus Numerical Rating Scale 0/1 (no itch/mild itch). There were no new safety signals.

Conclusion: Abrocitinib demonstrated early and sustained improvement in skin clearance and itch through week 112 in adult and adolescent patients, and sustained responses were observed in patients in the moderate and severe baseline AD subgroups.

Clinical trials registration: This study was a pooled analysis of data from the phase 3 JADE COMPARE (NCT03720470) and JADE EXTEND (NCT03422822) trials.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01937-1.

Related

  1. Can fluoxetine's diminished efficacy in pediatric depression be explained by study sites, baseline severity, age, and psychological interventions? A secondary exploratory meta-regression
    Martin Plöderl, Richard Lyus, Florian Naudet
    Journal of Psychiatric ResearchPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyHAL
  2. Baseline depressive-symptom severity and divergent psychological trajectories during GIP and/or GLP-1 receptor agonist therapy: a prospective ecological momentary assessment study
    Aika Miya, Michihiro Kaneko, Yuka Ozaki +2
    Diabetology internationalPeer-reviewedLicence not statedFull textEndocrinology & metabolismPMC
  3. Educational Artificial Intelligence Software to Support Assessment of Atopic Dermatitis Severity
    Kenichi Yamanaka, Yağmur Pak, Yoshihiro Inda +4
    The Journal of DermatologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  4. Associations of Total IgE, Eosinophils, and IL-5 with SCORAD-Defined Severity in High-IgE Atopic Dermatitis: A Retrospective Exploratory Study.
    Wenping Ma, Jie Liu, Rui Li +1
    Clinical, cosmetic and investigational dermatologyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. Nasal methicillin-resistant in adult atopic dermatitis: Severity and virulence associations—A cross-sectional study
    Athoob A Jomah, Yasmine Alshammari, Amani H Al-Fadhli +5
    Journal of International Medical ResearchPeer-reviewedCC BY-NCFull textInfectious diseaseDOAJ

Cite

BibTeXRIS
BibTeX
@article{pink2026does,
  title = {{Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials}},
  author = {Andrew E. Pink and Zakiya P. Rice and Melinda J. Gooderham and Fang Wang and Andreas Wollenberg and Pinaki Biswas and Gary Chan and Justine Alderfer and Melissa Watkins},
  journal = {Dermatology and Therapy},
  year = {2026},
  month = oct,
  doi = {10.1007/s13555-026-01937-1},
  url = {https://doi.org/10.1007/s13555-026-01937-1},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials
AU  - Andrew E. Pink
AU  - Zakiya P. Rice
AU  - Melinda J. Gooderham
AU  - Fang Wang
AU  - Andreas Wollenberg
AU  - Pinaki Biswas
AU  - Gary Chan
AU  - Justine Alderfer
AU  - Melissa Watkins
PY  - 2026
DA  - 2026/10/08
JO  - Dermatology and Therapy
DO  - 10.1007/s13555-026-01937-1
UR  - https://doi.org/10.1007/s13555-026-01937-1
AB  - Introduction: Baseline severity of atopic dermatitis (AD) may influence treatment response. The objective of this analysis was to assess short- and long-term abrocitinib efficacy and safety by baseline AD severity.  Methods: A post-hoc analysis of patients (aged ≥ 12 years) with moderate-to-severe AD receiving abrocitinib 100 mg or 200 mg or placebo in two studies—JADE COMPARE (ClinicalTrials.gov ID: NCT03720470) and JADE EXTEND (NCT03422822)—was performed. Baseline severity was assessed by several measures, including the Investigator’s Global Assessment (IGA) and the Eczema Area and Severity Index (EASI). Efficacy and safety endpoints were stratified by baseline severity.  Results: Higher proportions of patients with moderate or severe baseline AD achieved IGA score 0/1 (clear/almost clear) with abrocitinib at week 16 (moderate: 40.8% [100 mg], 50.0% [200 mg]; severe: 19.1% [100 mg], 43.2% [200 mg]) versus placebo (moderate: 18.0%; severe: 2.8%). At week 112, IGA 0/1 was achieved by high proportions of patients receiving abrocitinib with moderate (60.2% [100 mg], 64.3% [200 mg]) or severe (38.6% [100 mg], 54.5% [200 mg]) disease. Response rates were similar with other measures, including co-achievement of EASI-90 (90% improvement from baseline score) and Peak Pruritus Numerical Rating Scale 0/1 (no itch/mild itch). There were no new safety signals.  Conclusion: Abrocitinib demonstrated early and sustained improvement in skin clearance and itch through week 112 in adult and adolescent patients, and sustained responses were observed in patients in the moderate and severe baseline AD subgroups.  Clinical trials registration: This study was a pooled analysis of data from the phase 3 JADE COMPARE (NCT03720470) and JADE EXTEND (NCT03422822) trials.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01937-1.
SN  - 2193-8210
SN  - 2190-9172
SN  - 1476-5829
ER  -